Primary aldosteronism is increasingly investigated in hypertension being associated with an elevated cardiovascular risk. Aldosterone has been reported to increase in the luteal phase in normal women but to our knowledge the influence of the ovarian cycle on the first screening for primary aldosteronism (that is, on the levels of plasma aldosterone and its relationship to PRA levels) was never investigated. We measured hormonal levels during one cycle in 26 low-renin mild hypertensive outpatients. LH, FSH, 17 b-estradiol, progesterone, aldosterone and PRA were assayed at the seventh, fourteenth, twenty-first and twenty-eighth days of the cycle after 30 min of recumbency. Aldosterone and PRA increased from the seventh (follicular phase) to twentyfirst day (luteal phase) from 11.2 to 17.8 ng 100 ml À1 and from 0.23 to 0.35 ng ml À1 h À1 , respectively (both P ¼ 0.004) The proportion of patients with aldosterone 415 ng 100 ml À1 significantly increased from the follicular to the luteal phase, (8/26 vs 19/25, P ¼ 0.018); a similar increase was found for Aldosterone-PRA Ratio 430 combined with either a minimum PRA value of 0.5 ng ml À1 h À1 or aldosterone 415 ng 100 ml À1 (7/26 vs 16/25 and 7/26 vs 17/25 respectively, Po0.05).
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Introduction
The growing interest in the detection and treatment of arterial hypertension in the general population and, particularly, in the diagnosis of primary aldosteronism will conceivably bring more and more women of fertile age to medical attention. Primary aldosteronism has been increasingly recognized as a secondary form of hypertension with a far greater prevalence than previously suspected [1] [2] [3] [4] and attention to aldosteronism is also increased because it bears a high cardiovascular and cerebrovascular risk. 5, 6 A low-renin profile represents a hallmark of this condition but it is not clear to what extent it overlaps with the so-called 'low-renin (essential) hypertension' which is thought to affect about onethird of the hypertensive population and indicate a sodium volume-dependent hypertension deserving appropriate treatment. [7] [8] [9] [10] There is general agreement that the diagnostic protocol for primary aldosteronism requires a multi-step evaluation and should begin with a first-step laboratory screening, followed, when appropriate, by confirmation tests and further functional and anatomical evaluation.
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The first laboratory screening for primary aldosteronism basically relies on the determination of aldosterone, renin (usually plasma renin activity-PRA) and their ratio (usually expressed as aldosterone/renin ratio-ARR), but, as reported in the most recent international guidelines, 'the usefulness of these measurements is (still) controversial'. 14 ARR has been proposed as the most sensitive screening test, 3, 5, [11] [12] [13] 15 but it has been criticized because it predominantly depends on low PRA values 5, 9, 16, 17 and because of its low specificity. 18 For this reason combined criteria including also an aldosterone level above a minimal threshold have been proposed. 5, 11, 16, 18 However, all the biochemical parameters are affected by a significant variability and the laboratory screening still requires a definite standardization. Aldosterone levels are known to vary considerably in the same subject and various factors have been identified that affect this variability; among them sodium and potassium balance, posture, circadian rhythm and drug treatment are well known. 19, 20 Another determinant of aldosterone variability that has been identified in normal women is the ovarian cycle [21] [22] [23] [24] but this has not so much been taken into account in hypertension.
In our clinical experience 25 in low-renin hypertensive women we have observed that aldosterone levels often substantially vary when re-assayed, adding further uncertainty to the diagnostic workup for primary aldosteronism. These considerations prompted us to assess whether and to what extent the ovarian cycle could influence plasma aldosterone variability in women with low renin, in whom primary aldosteronism could be suspected. Furthermore, we assessed how this variability could affect the performance of diagnostic cutoffs of laboratory parameters for the initial screening of primary aldosteronism.
Materials and methods

Patients
We investigated 26 consecutive non-menopausal mildly-hypertensive female outpatients (mean age 42. 8, 6.2 s.d., range 31-55 years), who had lowrenin levels (PRAo0.65 ng ml À1 h À1 ) 7, 8 in the morning (0900-0930 h) in supine position for 30 min, after at least 1 week of pharmacological treatment discontinuation and with no sodium restriction. Six women had never been treated for hypertension before. None had been taking antialdosterone drugs or diuretics, had resistant hypertension, hypertensive organ damage or active medical problems, was pregnant or was taking exogenous estrogens or progestins for the previous 6 months. None had potassium levels below the normal limits. Blood pressure levels were in the range of mild hypertension in all subjects.
Procedures and laboratory methods
All patients gave their informed consent to the study; they were asked to discontinue previous antihypertensive treatment, to substitute it with low-dose amlodipine (2.5-5 mg per day) and to return at the seventh, fourteenth, twenty-first and twenty-eighth day of their next menstrual cycle provided that a minimum of 1 week was elapsed between treatment withdrawal and menstruation (otherwise they were asked to return on the following cycle). Amlodipine was discontinued at the first day of the cycle under study. At the scheduled days blood samples were taken at 0930 h after 30 min of supine position, plasma was assayed for LH, FSH, 17b-estradiol, progesterone (Beckman Coulter Unicell DxI800 Access Immunoassay System), aldosterone (ALDOCTK-RIA Diasorin, Saluggia, Italy), PRA (RENCTK-RIA Diasorin, Saluggia, Italy) and potassium (Beckman Coulter Cx 9 Pro Analyzer) and blood pressure was measured by Welch Allyn Vital Sign Monitor 300 Series in the last 18 patients.
Statistical analysis
The effect of the ovarian cycle on the parameters under investigation was assessed as follows. Variables found to be normal by Kolmogorov-Smirnov test were expressed as mean þ /À s.d. and were analyzed by repeated measurements analysis of variance with Bonferroni post hoc correction. The other variables were expressed by median, 25th and 75th percentiles and were analyzed by Friedman test; pairwise comparisons were done by Bonferroniadjusted Wilcoxon test. Proportions were compared by Fisher's exact test or w 2 test with continuity correction, as appropriate. A value of P less than 0.05 was considered statistically significant. All statistical analyses were done using SPSS package.
The performance of the diagnostic cutoffs was assessed taking into account the normal ranges of our laboratory (supine plasma aldosteronep 18 ng 100 ml À1 , PRAo0.65 ng ml À1 h À1 ) and other criteria reported in medical literature.
Results
As shown in Table 1 , the pituitary and ovarian hormones varied significantly along the cycle. Multiple comparisons demonstrated significant differences especially for progesterone, which had the most pronounced fluctuations with a maximum at the twenty-first day, in the luteal phase. Concomitant significant variations were observed for PRA and aldosterone with, respectively, significant and highly significant increments in the luteal phase, as indicated by multiple comparisons. PRA remained in the low range (highest value 1.15 ng ml À1 h
À1
). No significant effects were found for ARR, whose medians ranged between 40 and 50. Serum potassium and arterial blood pressure remained, respectively, in the normal limits and in the range of mild hypertension.
The number of women who resulted positive for various cutoffs of PRA, aldosterone, their ratio and other derived parameters in the different phases of the ovarian cycle are reported in Table 2 . As shown in the table, taking either 12 ng 100 ml À1,20 or 15 ng 100 ml À1,11,16,18,19 as cutoffs for aldosterone resulted in a significant difference in the proportion of positive results along the cycle. This difference was particularly evident for a cutoff of aldosterone415 ng ml À1 between the seventh and the twenty-first days, in which the proportion of positive cases more than doubled (from 8/26 ¼ 0.31 to 19/25 ¼ 0.76). No effects were observed for cutoffs based on PRA. The same was true for ARR except for a value of 430, when: (1) a minimum PRA value of 0.5 ng ml À1 h À1 was used to calculate the ratio, as proposed by Pimenta and Calhoun 5, 16 or (2) when ARR was used in combination with a value of plasma aldosterone415 ng 100 ml À1 , as suggested by other authors. 11, 16, 18 Significant positive correlations were observed for pooled data between aldosterone and both PRA and 
Discussion
It has been known that plasma aldosterone and renin activity may oscillate in normal women during the ovarian cycle usually increasing in the luteal phase, [21] [22] [23] [24] but to our knowledge no report has addressed the potential relevance of this aspect in the first-step laboratory screening of primary aldosteronism in low-renin hypertensive women and no recommendation is made on this aspect in the practical guidelines.
14 A major finding of this study is that in these patients plasma aldosterone consistently increased during the ovarian cycle being highest in the luteal phase (indeed in 8 out of 25 women it more than doubled from the seventh to the twenty-first day and 12 women had values below a threshold of 15 ng 100 ml À1 at the seventh day and above this threshold at day 21). This may have practical diagnostic consequences because in the same Our results indicate that the ovarian cycle may influence to different degrees the screening for primary aldosteronism depending on the choice of parameters and cutoff points. Screening with the use of ARR, as the only parameter, was not significantly affected by the ovarian cycle. This may lead to the reassuring conclusion, if confirmed in further studies with the definite diagnosis of primary aldosteronism as the gold standard, that ARR is the best index to be used to avoid the confounding effect of the cycle. However, the use of ARR per se is controversial 14 and has been questioned for various reasons, including the fact that, for low PRA levels, ARR is strongly dependent on PRA itself and, as observed by Padfield, 9 in this situation 'almost by definition, low-renin hypertension is reclassified as hyperaldosteronism' with the consequence of submitting a large number of subjects to costly and potentially stressful and unnecessary examinations. A further concern with low PRA values is their low accuracy, because they are in the low limit of the RIA standard curve. For these reasons it has been proposed to improve the accuracy of ARR by increasing the minimum PRA level in the ratio or by requiring a minimum aldosterone level. 5, 11, 16, 18 Following these approaches we have examined different criteria and cutoffs, including those proposed for the supine position 19, 20, 26 and found that ARR becomes significantly dependent on the ovarian cycle when coupled with either a minimum PRA level of 0.5 ng ml À1 h À1 or a minimum aldosterone level of 15 ng 100 ml À1 . Finally, if one looks only at supine aldosterone levels, the influence of the ovarian cycle is clearly evident using a cutoff of plasma aldosterone415 ng 100 ml À1 , comparable to that considered by Tanabe. 19 Some limitations of the study should be mentioned. Firstly, although the diagnostic work-up for primary aldosteronism is still controversial, 11, 12, 16, 17, 26 according to the prevailing experts opinion, [11] [12] [13] the determination of PRA and aldosterone represents the first screening test, that should be followed by a confirmatory test (for example, fludrocortisone test, captopril test or saline infusion) that investigates the autonomous aldosterone secretion. Therefore, as no definite diagnosis of primary aldosteronism was made in our patients, our conclusions do not allow to establish the relevance of the ovarian cycle on the overall diagnostic process for the disease, which requires further studies. Similarly, no indication can be provided at present if there is an optimal timing for blood testing.
Secondly, we cannot exclude that in some patients a carryover effect of discontinuation of amlodipine as well as other preceding treatments may have amplified the increase of plasma aldosterone in the second part of the cycle. However, amlodipine, especially at the low dosages employed in our study, is known to be one of the drugs that least affect aldosterone levels. 13, 27 In addition, as regards the other treatments, only five out of the 26 patients had discontinued previous treatment for less than 2 weeks (but more than 1 week) and aldosterone peaked at the twenty-first day in the majority of women corresponding to the progesterone peak, as observed also in normotensive women. 24 Finally, the aldosterone behavior during the cycle appeared similar in the six women who had never been treated.
Another aspect that one may consider as a limitation is that blood sampling was done in the supine position, which is not the most used condition for aldosterone and renin sampling. However, the patient posture and its time length for aldosterone and PRA testing is not yet standardized and indeed a variety of conditions have being employed, including recumbency. 3, 11, 12, [18] [19] [20] 26 In our case the supine position was chosen as a the most 'baseline' condition, to minimize sympathetic stimulation because of possible environmental factors and enhance the detectability of the cycle effects on PRA and aldosterone variability.
A few pathophysiological considerations may be added. Firstly, the physiological relation between PRA and aldosterone was maintained throughout the cycle despite a low-renin profile (as suggested by the significant positive correlation between the two parameters). This could reflect a supersensitivity of the adrenal cortex to angiotensin II in low-renin hypertension. 28 Secondly, aldosterone and progesterone were positively related throughout the cycle confirming previous observations in normal women. 24 Progesterone may affect aldosterone levels in several direct or indirect ways. In fact, progesterone (1) Is a natural precursor of aldosterone; (2) stimulates aldosterone secretion in vitro and in vivo; 24, 29, 30 (3) is a mineralocorticoid receptor antagonist; (4) has a direct natriuretic effect 24, 29, 31, 32 that in turn may indirectly stimulate aldosterone secretion. Finally, the aldosterone increase in the luteal phase may be mediated by LH that, in addition to induce progesterone secretion in the ovary, may also stimulate aldosterone synthesis in the adrenal cortex. [33] [34] [35] Perspectively, the growing interest in the detection and treatment of arterial hypertension in the general population (with a trend to decreasing threshold blood pressure levels) and, particularly, in the diagnosis of primary aldosteronism, will conceivably bring more and more women of fertile age to medical attention. In these women, screening for secondary forms of hypertension (and thus also for primary aldosteronism) will be frequent and probably a standardization will be needed of the timing of blood samples with respect to the phases of the ovarian cycle. In the meantime, it would be probably advisable, in a hypertensive woman in her fertile age submitted to aldosterone and PRA determinations for aldosteronism, to inquire about her cycle phase at the time of blood sampling and to take into account the magnifying effect of the luteal phase on aldosterone levels. However, which is the optimal testing time cannot be answered yet requiring an ultimate diagnosis of the disease, which was not obtained in this study. A final consideration is that, irrespective of the final diagnosis, 'abnormally' high aldosterone levels seem to occur frequently in the luteal phase of low-renin hypertensive women. If confirmed, this factor could have also therapeutic implications, suggesting the need for investigating the efficacy and safety of aldosterone antagonists in these female populations.
